-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since March, the pharmaceutical and biological industry, which has undergone a long-term valuation adjustment, is still favored by institutions
.
Judging from the number of institutional investigators, Puluo Pharmaceuticals, Mindray Medical, Haier Biology, Changchun Hi-Tech and other pharmaceutical stocks have been investigated by more than 100 institutions
.
Among them, Puluo Pharmaceutical, Mindray Medical, and Changchun High-tech have accumulated more than 200 investigators during the period
.
Since March, Puluo Pharmaceutical has received a total of 215 institutional surveys, including top public offerings such as E Fund, Industrial Securities, GF, and Bosera, insurance funds such as China Life Pension Insurance, and leading foreign investors such as GSAM and PAG Investment
.
Institutions mainly focus on the company's disclosure time in the first quarter, new growth points of CDMO business, and future development priorities
.
Puluo Pharmaceutical is a large-scale comprehensive pharmaceutical enterprise integrating research, development and production of APIs, preparations and pharmaceutical intermediates
.
According to the company's development strategy of "making refined raw materials, strengthening CDMO, and making excellent preparations", in the future, it will focus on developing the company's strategic varieties with advantages in cost, quality, technology, etc.
and the CDMO business, through increasing investment in R&D and projects, to continuously improve the company's core competitiveness
.
Mindray Medical released a record of investor relations activities on March 20, and the company received surveys from 346 institutions on March 18, 2022
.
In the interactive Q&A session, the organization mainly focused on the impact of DRG/DIP and the implementation of mutual recognition of test results on the total test volume in the future, the company's future development strategy in developing countries, the progress of medical treatment in overseas markets, the recent The impact of rising commodity prices on company costs,
etc.
The company is mainly engaged in the research and development, manufacturing, marketing and service of medical devices.
Its main products cover three major fields: life information and support, in vitro diagnosis and medical imaging
.
The company is headquartered in Shenzhen, China, and has 40 overseas subsidiaries in more than 30 countries in North America, Europe, Asia, Africa, Latin America and other regions; 17 subsidiaries and more than 40 branches in China, forming a huge A global R&D, marketing and service network
.
Changchun Hi-Tech has also received frequent attention from institutions since March, and received more than 200 institutions on March 17 and March 18 respectively.
.
Changchun High-tech is the leading domestic growth hormone enterprise, with complete recombinant human growth hormone injection (powder injection), recombinant human growth hormone injection (water injection), polyethylene glycol recombinant human growth hormone injection (long-acting water injection) needles) full product line
.
Institutions are very concerned about the company's powder needles being included in centralized procurement
.
On March 10, the results of the coalition centralized procurement led by 11 provinces and autonomous regions in Guangdong Province were announced
.
In the institutional survey on March 17, Changchun High-tech stated that "the long-acting water injection has now begun to adjust the product price, and after the adjustment, more patients can enjoy the preferential price similar to the previous related public welfare activities
.
The company is increasing its efforts.
Make every effort to promote long-acting growth hormone
.
" According to a notice issued by the Qinghai Provincial Medicine Collection Center on March 17 on adjusting the prices of some medicines
.
The price of the polyethylene glycol recombinant human growth hormone injection (long-acting water injection) (specification: 54IU/9.
0 mg/1.
0ml) of Jinsai Pharmaceutical, a subsidiary of Changchun High-tech, has been adjusted from the original 5600 yuan to 3500 yuan.
A drop of 37.
5%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Judging from the number of institutional investigators, Puluo Pharmaceuticals, Mindray Medical, Haier Biology, Changchun Hi-Tech and other pharmaceutical stocks have been investigated by more than 100 institutions
.
Among them, Puluo Pharmaceutical, Mindray Medical, and Changchun High-tech have accumulated more than 200 investigators during the period
.
Since March, Puluo Pharmaceutical has received a total of 215 institutional surveys, including top public offerings such as E Fund, Industrial Securities, GF, and Bosera, insurance funds such as China Life Pension Insurance, and leading foreign investors such as GSAM and PAG Investment
.
Institutions mainly focus on the company's disclosure time in the first quarter, new growth points of CDMO business, and future development priorities
.
Puluo Pharmaceutical is a large-scale comprehensive pharmaceutical enterprise integrating research, development and production of APIs, preparations and pharmaceutical intermediates
.
According to the company's development strategy of "making refined raw materials, strengthening CDMO, and making excellent preparations", in the future, it will focus on developing the company's strategic varieties with advantages in cost, quality, technology, etc.
and the CDMO business, through increasing investment in R&D and projects, to continuously improve the company's core competitiveness
.
Mindray Medical released a record of investor relations activities on March 20, and the company received surveys from 346 institutions on March 18, 2022
.
In the interactive Q&A session, the organization mainly focused on the impact of DRG/DIP and the implementation of mutual recognition of test results on the total test volume in the future, the company's future development strategy in developing countries, the progress of medical treatment in overseas markets, the recent The impact of rising commodity prices on company costs,
etc.
The company is mainly engaged in the research and development, manufacturing, marketing and service of medical devices.
Its main products cover three major fields: life information and support, in vitro diagnosis and medical imaging
.
The company is headquartered in Shenzhen, China, and has 40 overseas subsidiaries in more than 30 countries in North America, Europe, Asia, Africa, Latin America and other regions; 17 subsidiaries and more than 40 branches in China, forming a huge A global R&D, marketing and service network
.
Changchun Hi-Tech has also received frequent attention from institutions since March, and received more than 200 institutions on March 17 and March 18 respectively.
.
Changchun High-tech is the leading domestic growth hormone enterprise, with complete recombinant human growth hormone injection (powder injection), recombinant human growth hormone injection (water injection), polyethylene glycol recombinant human growth hormone injection (long-acting water injection) needles) full product line
.
Institutions are very concerned about the company's powder needles being included in centralized procurement
.
On March 10, the results of the coalition centralized procurement led by 11 provinces and autonomous regions in Guangdong Province were announced
.
In the institutional survey on March 17, Changchun High-tech stated that "the long-acting water injection has now begun to adjust the product price, and after the adjustment, more patients can enjoy the preferential price similar to the previous related public welfare activities
.
The company is increasing its efforts.
Make every effort to promote long-acting growth hormone
.
" According to a notice issued by the Qinghai Provincial Medicine Collection Center on March 17 on adjusting the prices of some medicines
.
The price of the polyethylene glycol recombinant human growth hormone injection (long-acting water injection) (specification: 54IU/9.
0 mg/1.
0ml) of Jinsai Pharmaceutical, a subsidiary of Changchun High-tech, has been adjusted from the original 5600 yuan to 3500 yuan.
A drop of 37.
5%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
